Clinical Trial

A Study of Guselkumab Administered Subcutaneously in Treatment of Indian Participants With Psoriatic Arthritis (PsA)

Name: A Study of Guselkumab Administered Subcutaneously in Treatment of Indian Participants With Psoriatic Arthritis (PsA) — clinical trial record (NCT07141004)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 4

View on ClinicalTrials.gov →

Summary

The purpose of this study is to evaluate the safety and how well guselkumab treatment works (efficacy) in participants with psoriatic arthritis (PsA; a chronic, autoimmune form of arthritis that causes joint inflammation) who had inadequate response to standard therapies.

Trial Details

NCT Number	NCT07141004
Lead Sponsor	Johnson & Johnson Private Limited
Conditions	Arthritis, Psoriatic
Enrollment	100 participants
Start Date	2025-08-12
Primary Completion	2027-06-05 (estimated)
Study Completion	2027-09-11 (estimated)
Updated on ClinicalTrials.gov	2026-07-06